Cadrenal Therapeutics (CVKD) Competitors

Procaps Group (NASDAQ:PROC) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation.

Which has preferable valuation & earnings, PROC or CVKD?

Procaps Group has higher revenue and earnings than Cadrenal Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Procaps Group	$409.92M	0.26	$42.54M	N/A	N/A
Cadrenal Therapeutics	N/A	N/A	-$10.65M	-$9.26	-1.21

Does the media prefer PROC or CVKD?

In the previous week, Procaps Group's average media sentiment score of 0.00 equaled Cadrenal Therapeutics'average media sentiment score.

Company	Overall Sentiment
Procaps Group	Neutral
Cadrenal Therapeutics	Neutral

Which has more risk and volatility, PROC or CVKD?

Procaps Group has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Is PROC or CVKD more profitable?

Procaps Group's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Procaps Group	N/A	N/A	N/A
Cadrenal Therapeutics	N/A	-244.94%	-181.94%

Do institutionals and insiders believe in PROC or CVKD?

7.9% of Cadrenal Therapeutics shares are held by institutional investors. 19.9% of Procaps Group shares are held by insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts prefer PROC or CVKD?

Cadrenal Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 184.70%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Procaps Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Procaps Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cadrenal Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor PROC or CVKD?

Cadrenal Therapeutics received 4 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 87.50% of users gave Cadrenal Therapeutics an outperform vote while only 37.50% of users gave Procaps Group an outperform vote.

Company	Underperform	Outperform
Procaps Group	Outperform Votes 3 37.50%	Underperform Votes 5 62.50%
Cadrenal Therapeutics	Outperform Votes 7 87.50%	Underperform Votes 1 12.50%

Summary

Cadrenal Therapeutics beats Procaps Group on 8 of the 12 factors compared between the two stocks.